The CRO Isn't Failing Your Trial — Your Governance Model Is
核心洞察
Clinical operations leaders argue that sponsors who treat a signed work order as a substitute for leadership are the architects of their own trial failures.
Tufts CSDD data shows only one in five sponsors rate their oversight processes as highly effective, exposing a widespread governance deficit.
The Applied Therapeutics case demonstrates that delegation does not transfer accountability, as the FDA warning letter went to the sponsor, not the CRO.
Robert Goldman, who has run global clinical operations for years, offered a blunt diagnosis this week that drew 208 likes and 66 comments: sponsors who treat a signed work order as a substitute for leadership are the architects of their own trial disasters. "The worst studies had sponsors who thought a signed work order was a substitute for leadership," Goldman wrote. "No CRO partnership is stronger than the sponsor behind it."
Within hours, two other credible clinical operations voices published their own versions of the same argument. The overlap was not coordinated — and that, practitioners say, is precisely what makes it significant. What these voices describe is not a vendor performance problem but a governance deficit sitting at the center of an industry that has convinced itself delegation and accountability are the same thing.
The Handoff Illusion
The scenario playing out across small biotech portfolios follows a familiar arc. A sponsor completes a competitive CRO bid process, awards the contract, celebrates the milestone internally, and then progressively reduces its own operational involvement. Weekly calls replace strategic engagement. Status reports replace site-level scrutiny. The CRO says "we're on track," and the sponsor — lacking the internal expertise to interrogate that claim — accepts it. Six months later, enrollment is behind and the trial master file (TMF) has gaps no one caught in real time.
Goldman's framing cuts through the industry's euphemisms: CROs are hired to extend sponsor capabilities, not to replace sponsor leadership. The moment a sponsor confuses those two functions, the trial is running without a captain.
Elena Sinclair identified the deeper structural problem with precision: most small biotechs do not fail because the molecule was wrong. They fail because no one sponsor-side was qualified to challenge the trial. Sinclair cited Tufts CSDD data showing only one in five sponsors rate their oversight processes as highly effective. Four out of five sponsors, by their own assessment, are operating oversight processes they do not consider highly effective — yet the industry continues to treat CRO award as the end of the governance conversation rather than the beginning of it.
The Applied Therapeutics Warning
The regulatory system has already answered the question of where accountability lives when delegation goes wrong. Sinclair's post surfaces the example the industry should be studying: Applied Therapeutics. A vendor deleted 47 patients' primary endpoint data. The FDA's warning letter went to Applied Therapeutics, not the CRO. Delegation did not transfer accountability; the sponsor owned the data integrity obligation regardless of which organization's employees were touching the database.
This is not a novel regulatory position. ICH E6(R2), the GCP guideline governing sponsor responsibilities, is explicit that sponsors retain ultimate responsibility for the quality and integrity of trial data regardless of which tasks have been delegated to a CRO. The FDA's 2023 guidance on oversight of clinical investigations reinforces the same principle: sponsors must establish and maintain oversight processes sufficient to verify that delegated functions are being performed. The Applied Therapeutics case is what happens when those processes exist on paper and nowhere else.
Sinclair's diagnostic questions should be read as a protocol for every small biotech board meeting that touches clinical operations: What is your eTMF completeness percentage right now? Who is the CRA at your top-enrolling site, and how experienced are they? When did you last review a monitoring visit report, not just receive it? Did your ClinOps lead design the governance plan, or did the CRO hand it to you? If a sponsor cannot answer those questions in real time, it does not have oversight — it has an account relationship.
The Expertise Gap No One Budgets For
The counterintuitive reality Goldman and Sinclair both circle is that the sponsors most dependent on CRO capability are precisely the sponsors least equipped to oversee it. Small biotechs operating lean, pre-commercial teams frequently lack a single internal employee qualified to evaluate clinical monitoring plan adequacy, interrogate CRO staffing turnover patterns, or conduct a meaningful TMF audit. They hire a CRO because they cannot afford to build the function internally, and then discover too late that overseeing a CRO competently requires nearly the same expertise as running the function themselves.
Goldman's observation that the best studies he has seen had sponsors deeply engaged in strategy, governance, decision-making, and oversight is not a prescription for redundancy. It is a description of what effective partnership actually requires. The sponsor brings therapeutic knowledge, regulatory strategy, and accountability that no CRO can contractually absorb. The CRO brings operational scale, site networks, and execution infrastructure. Neither half of that equation functions without the other.
For small biotechs without internal ClinOps leadership qualified to own oversight, Sinclair names one structural option directly: a fractional Head of Clinical Operations whose job is not to manage the CRO but to prevent the sponsor from pretending oversight exists when it does not.
Measure Twice, Cut Once
Cindy Henderson, founder of Henderson Consulting LLC (搜索), extends the argument from oversight to protocol design. A protocol amendment in a Phase 2 or 3 trial costs anywhere from $141,000 to $535,000, according to data from the Tufts Center for the Study of Drug Development (搜索). Yet 76% of Phase 1-4 trials now require at least one amendment, up from 57% in 2015.
Henderson argues that the CRO's value is not execution alone but the depth of perspective that comes from having seen hundreds, sometimes thousands, of trials across disease areas, geographies, and regulatory environments. Experienced CRO personnel know which endpoint strategies have caused problems at the FDA, which eligibility criteria look reasonable on paper and prove impossible to operationalize in the field, and which site networks can realistically support a given design. That knowledge is most valuable at the design stage — not after the protocol is final.
Two structural problems arise when the protocol is developed internally and handed to the CRO for execution. First, endpoints: the total number collected in trials has nearly doubled over the past decade, with too much nonessential data being collected. Second, inclusion and exclusion criteria: criteria that are too narrow are one of the most common — and most avoidable — causes of enrollment failure.
Henderson also assigns responsibility to CROs themselves, which "default to vendor mode just as often as sponsors fail to engage them as thought partners." A CRO in vendor mode receives the protocol, prices the work, and executes against the specification, withholding the operational concerns it can already see in the design. The right posture, she argues, is the opposite: press for the protocol draft as early as possible and bring forward problems with proposed solutions.
The Investor Pressure Problem
A force working against all of this is investor pressure around the first patient in milestone. For biotech companies funded by venture capital or operating under public market scrutiny, first patient in signals progress, unlocks tranches of funding, and demonstrates execution. The pressure to reach it quickly creates a perverse incentive to compress exactly the phase that most deserves time.
"First patient in is not the goal," Henderson writes. A well-designed trial with appropriate CRO involvement, robust eligibility criteria, and a thoughtfully scoped endpoint strategy will reach first patient in later — and finish the trial faster, with cleaner data.
The Collaborative Bid Model
The sponsor-CRO relationship is shaped by how the bidding process is structured. In the specification model, the sponsor finalizes the protocol internally and sends a completed specification to prospective CROs, who bid on price and execution. The relationship begins as a vendor relationship and tends to stay that way.
In the collaborative bid model, the sponsor shares a protocol draft — not a final specification — during the bidding process and invites CROs to engage with it scientifically. The bid defense becomes a thought partner exercise, and the relationship begins with intellectual engagement that tends to sustain it. The practical difference is significant: the sponsor learns how each CRO thinks, whether they challenge assumptions respectfully, and whether their scientific team engages seriously with the protocol.
Henderson's single most valuable structural recommendation is the roundtable: bring all stakeholders together early, in the same room, around the same protocol — not sequentially, but together. The CMO, the CRO, the medical writer, the statistician, sponsor executives, clinical operations, and regulatory affairs. In one oncology trial, a CRO medical writer flagged 10 items across the protocol; two of her suggestions were implemented directly, but the sponsor's CMO said afterward that her willingness to challenge the team changed how everyone thought about the design.
"The governance model is the trial," the practitioners conclude. Every sponsor that has not internalized that reality is one warning letter away from learning it the hard way.